TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04086290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
Study: NCT01303302

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tantalus System
Description: The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TANTALUS system
Description: The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes. In the sham comparator the device is off.
Study: NCT04194918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Smoking Cessation Intervention
Description: Use the Flexiquit+ program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive text messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handout
Description: Receive handouts via email

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00115856

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Intravascular MRI
Description: Arterial imaging of atherosclerosis
Study: NCT03200496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5206(Fasting)
Description: Test drug l : DA-5206(Fasting)
Study: NCT04194918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT02469714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigator Intervention
Description: Peer navigators will be Hispanics/Latinos with a mental illness in recovery who will complete and meet certification for the peer navigator training program that will be evolved out of the mixed methods process. Investigators propose the peer navigators will enhance patient engagement in integrated care which will, in turn, improve physical and mental health and wellness of patients in this group
Study: NCT02688868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FirehawkTM 2.25mm
Description: Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems
Study: NCT01470833

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early weight-bearing
Description: The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weight-bearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weight-bearing is allowed. Week 5 to 8 Full weight-bearing is allowed. Crutches should be avoided.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made.
Study: NCT01113489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate
Description: 400 mcg/1 ml b.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 ml b.i.d.
Study: NCT00100295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum
Description: 300 mg capsule taken three times a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg given three times a day, containing rice protein powder
Study: NCT01172730

Intervention type: DEVICE
Intervention: Ultrasound scanning
Description: Ultrasound scanning is used to define needle insertion point and depth of epidural space.
Study: NCT04437719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obvio-19 app
Description: As part of this research, the patient must complete questionnaires daily on the Obvio-19 application, one of 5 minutes.~Evaluation of the proportion of patients with COVID-19 infection's symptoms known to be associated with COVID-19 diagnosis (fever, cough, loss of taste and smell, sore throat, muscle pain, diarrhea, fatigue, difficulty eating and drinking and shortness of breath) followed during a period of 6 months.~To assess the prevalence and course of symptoms of COVID-19 infection of patients followed during a period of 6 months.~To establish the correlation of the COVID-19 infection with the biological and clinical data of patients from the Oncology cohort of the Groupe hospitalier Paris Saint-Joseph in Paris followed during a period of 6 months.
Study: NCT04388046

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Herbst fixed functional appliance
Description: Herbst appliance could be considered as an artificial joint working between maxilla and mandible. The appliance consists of a bilateral telescope mechanism attached to upper and lower jaws keeping the mandible in an anterior jumped position.
Study: NCT04773873

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFM Crowns on gold coping cast-on
Description: Classic impressions are taken by the operators and sent to one and same laboratory who will deliver all the screw-retained PFM restorations. The crowns will be made using a gold coping cast-on synOcta gold abutment (Ceramicor) for wide (WN) or regular (RN) neck

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hybrid abutment lithium disilicate crown
Description: Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (e.max CAD). crystallization/ characterization/ glaze firing for the e.max CAD crown using an oven with specific firing programmes for e.max CAD. Adhesive cementation steps of the ceramic crown onto the TiBase

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hybrid abutment ceramic polymer infiltrated crown
Description: Intraoral digital impression with respective scanbodies (Sirona) for Cerec OmniCam or Cerec Bluecam over the chosen TiBase. Cerec CAD designing (operator) and CAM milling (Cerec MCXL) of single crowns with perforated blocs (Enamic). Surface polishing with rubber polishers. Adhesive cementation steps of the ceramic crown onto the TiBase
Study: NCT01183819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space Fortress
Description: Space Fortress sessions 3 times a week for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Aerobic Exercise 4 times a week for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic Exercise 4 times a week for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching/Toning exercise 4 times a week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Games
Description: Control games session 3 times a week for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Games
Description: Control games session 3 times a week for 12 weeks
Study: NCT02772796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SENS-218
Description: Oral Administration
Study: NCT01420627

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EZN-2279
Description: Weekly administration of EZN-2279 via IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adagen
Study: NCT03635034

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insert bladder catheter
Description: Bladder catheter will be inserted according to randomization schema

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No catheter
Description: Subjects will not receive a bladder catheter during the ablation procedure
Study: NCT01560052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Original Cohort:~Oral methylprednisolone or placebo 0.8mg/kg/day with a maximum of 48mg/day x 2months, taper by 8mg/day every month, patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines~Low Dose Cohort:~Oral methylprednisolone or placebo 0.4mg/kg/day with a maximum 32mg/day and minimum of 24mg/day then reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy.
Study: NCT04005612

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: 50,000 IU VD3 / week for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: 300 mg of omega 3-FA once daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: 300 mg of omega 3-FA once daily for 8 weeks
Study: NCT03200496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5206(Fed)
Description: Test drug ll : DA-5206(Fed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALION®
Description: Reference drug : Talion®
Study: NCT01076881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Study: NCT04011462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prewarming 20 minutes
Description: prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prewarming 30 minutes
Description: prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
Study: NCT01076881

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Study: NCT04002531

Intervention type: OTHER
Group type: OTHER
Intervention: General and Neurological examination
Description: Information about your general health, neurological symptoms and current medications with be collected
Study: NCT04005612

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: 300 mg of omega 3-FA once daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 and omega-3 fatty acid
Description: 50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
Study: NCT04002531

Intervention type: OTHER
Group type: OTHER
Intervention: Vital signs
Description: Height, weight, blood pressure, heart rate, and respiratory rate and temperature will be measured.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 12 lead electrocardiogram
Description: A non-invasive test that measures the electrical activity of the heart
Study: NCT04005612

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 and omega-3 fatty acid
Description: 50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
Study: NCT04002531

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Echocardiogram
Description: A non-invasive sonogram of the heart

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: Blood will be drawn to evaluate general health and renal function (kidney health)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Urine collection
Description: Urine will be collection to evaluate renal function (kidney health)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 2-hour Holter Monitor
Description: A non-invasive test that measures the electrical activity of the heart continuously over 2 hours

Intervention type: OTHER
Group type: OTHER
Intervention: Brief Pain Inventory questionnaire
Description: A questionnaire about daily pain

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life questionnaire
Description: A questionnaire about the impact of disease on their activities of daily living and quality of life
Study: NCT00368056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: eszopiclone 3 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT04166435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide + Olaparib
Description: Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
Study: NCT06107712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online yoga exercise
Description: The basic yoga poses of Shivananda Yoga included in the online yoga group were shoulder stand (sarvangasana), plough pose (halasana), fish pose (matsyasana), backstretch (paschimothanasana), cobra (bhujangasana), locust (shalabhasana), bow (dhanurasana), spinal twist (matsyendrasana), crow pose (kakasana), standing backstretch (pada hasthasana) and triangle pose (trikonasana).~The yoga practice flow was designed for individuals who had never practiced yoga before. In the initial classes, there was a focus on breathing exercises and warming-up series such as Sun Salutations. The instructor frequently reminded the participants to perform all the poses with full yoga breaths and without holding their breath.~In the scope of the study, the physiotherapist researcher who is a certified as the Shivananda Yoga instructor, performed the same yoga practice flow and steps in the both groups during six-week.
Study: NCT04005612

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 and omega-3 fatty acid
Description: 50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: no intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: no intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: no intervention
Study: NCT04670276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injection of emulsified adipose tissue stromal vascular fraction
Description: Endoscopic injection of 10 cc of autologous microfat into the fistula (through a 6-French catheter), until it was completely filled, and a total of 1-2 cc of tSVFem (through a 22G endoscopic needle) into the submucosa of the 4 quadrants of the fistula borders, to obliterate it completely.
Study: NCT01753557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: MP-424: 750mg every 8 hours (q8h) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: MP-424: 750mg every 8 hours (q8h) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV: 600 - 1000 mg/day based on body weight for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV: 600 - 1000 mg/day based on body weight for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a
Description: PEG-IFN alfa-2a: 180mcg/week for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a
Description: PEG-IFN alfa-2a: 180mcg/week for 24 weeks
Study: NCT01927198

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 12.5 mg
Study: NCT02437903

Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM VOLUMA™ XC
Description: Subjects will receive up to 4, 1mL syringes of JUVÉDERM VOLUMA™ XC for their initial injection and a maximum of 6, 1mL syringes of JUVÉDERM VOLUMA™ XC for the study. Subjects will undergo one touch-up injection approximately 2 weeks post initial treatment, and will continue to be evaluated at month 1, month 3, month 6, month 9, and month 12.
Study: NCT02257697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CTX)
Study: NCT00636389

Intervention type: DEVICE
Group type: OTHER
Intervention: Polyflux 210H dialyzer
Description: Three consecutive treatments with the Polyflux 210H dialyzer. All study treatments will be performed in the standard hemodialysis mode.

Intervention type: DEVICE
Group type: OTHER
Intervention: Polyflux 210H dialyzer
Description: Three consecutive treatments with the Polyflux 210H dialyzer. All study treatments will be performed in the standard hemodialysis mode.

Intervention type: DEVICE
Group type: OTHER
Intervention: Polyflux HD-C4
Description: Three consecutive treatments with the Polyflux HD-C4 dialyzer. All study treatments will be performed in the standard hemodialysis mode.

Intervention type: DEVICE
Group type: OTHER
Intervention: Polyflux HD-C4
Description: Three consecutive treatments with the Polyflux HD-C4 dialyzer. All study treatments will be performed in the standard hemodialysis mode.
Study: NCT05656261

Intervention type: GENETIC
Intervention: Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys
Description: On day of enrollment, participants will have 1 blood sample obtained to extract DNA for determining their APOL1 genotype, and will answer a survey asking about their attitudes/beliefs on kidney disease, hypertension, and diabetes, as well as genetic testing. Participants will receive their results via telephone shortly thereafter, and then complete the same survey at 3 months and 12 months post-enrollment, in order to evaluate if any of their attitudes or beliefs have changed since knowing their APOL1 genetic test result. Those who are interested, specifically those who carry the homozygous or compound heterozygous renal risk variant, will have the option to speak with a designated genetic counselor who is associated with the study site and approved by the IRB.
Study: NCT02942030

Intervention type: OTHER
Intervention: Computerized assesment battery
Description: All participants will do a computerized assessment battery to identify specific attentional profile

Intervention type: OTHER
Intervention: Computerized assesment battery
Description: All participants will do a computerized assessment battery to identify specific attentional profile
Study: NCT03813810

Intervention type: OTHER
Intervention: Non
Description: There would be no interventions. Only measurements will be performed.

Intervention type: OTHER
Intervention: Non
Description: There would be no interventions. Only measurements will be performed.

Intervention type: OTHER
Intervention: Non
Description: There would be no interventions. Only measurements will be performed.

Intervention type: OTHER
Intervention: Non
Description: There would be no interventions. Only measurements will be performed.
Study: NCT01824043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal ranibizumab injections
Description: Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
Study: NCT03796052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avena Sativa Skincare Regimen
Description: Regimen consisting of 3 topical agents containing Avena Sativa (oat) kernel flour: a body wash (type = cosmetic), a body cream (type = cosmetic), and an anti-itch balm (type = OTC monograph drug with 0.5% Pramoxine HCl)
Study: NCT03086551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active continuous theta burst stimulation (cTBS)
Description: Active cTBS over dorsolateral prefrontal cortex that has an effect upon dorsolateral prefrontal cortex brain activity.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sham) continuous theta burst stimulation
Description: Sham stimulation over dorsolateral prefrontal cortex that looks and sounds like active cTBS but does not have any effect upon dorsolateral prefrontal cortex brain activity.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motor Practice
Description: Upper limb reaching task to be practiced. Practice will be paired with Active/Sham stimulation. Twenty trials will occur before Active/Sham stimulation. 40 trials will be practiced after Active/Sham stimulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Practice
Description: Upper limb reaching task to be practiced. Practice will be paired with Active/Sham stimulation. Twenty trials will occur before Active/Sham stimulation. 40 trials will be practiced after Active/Sham stimulation.
Study: NCT04831424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier social stress test
Description: The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier social stress test
Description: The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier social stress test
Description: The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trier social stress test
Description: The Trier social stress test (TSST) is a tool for investigating psychobiological stress responses in a laboratory setting. It is a laboratory procedure used to reliably induce stress in human research participants. The study is not examining or validating the test itself but rather using it as a tool to measure the response/focus of study.